Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Kunika, Kikumori"'
1
Akademický článek
Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase 3 Study by Stroke Type and Location
Autor: Koichi Hosomi, Yoichi Katayama, Hiroshi Sakoda, Kunika Kikumori, Masanori Kuroha, Takahiro Ushida
Publikováno v: Pain and Therapy, Vol 13, Iss 5, Pp 1151-1171 (2024)
Abstract Introduction Central post-stroke pain (CPSP) is a common type of central neuropathic pain (CNeP) that can occur following the onset of stroke. The oral gabapentinoid mirogabalin besylate (mirogabalin) is a selective α2δ ligand that is effe
Externí odkaz: https://doaj.org/article/4941dc716d7a456b8ed9d7efa39a2a97
Zobrazit plný text záznamu
2
Akademický článek
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 14-Week Study of Mirogabalin in Chinese Patients with Diabetic Peripheral Neuropathic Pain
Autor: Xiaohui Guo, Yang Yu, Yongbo Zhang, Li Sun, Yufeng Li, Bing Song, Li Hang, Masayuki Baba, Yosuke Wasaki, Kunika Kikumori, Emiko Murayama
Publikováno v: Pain and Therapy, Vol 13, Iss 4, Pp 937-952 (2024)
Abstract Introduction There is no approved effective drug for diabetic peripheral neuropathic pain (DPNP) in China. Gabapentinoids including mirogabalin have shown promise, although data in Chinese patients are scarce. Methods This phase 3, multicent
Externí odkaz: https://doaj.org/article/c3f2001e2c064e97977406da79a42222
Zobrazit plný text záznamu
3
Akademický článek
Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
Autor: Takahiro Ushida, Yoichi Katayama, Yoichi Hiasa, Makoto Nishihara, Fumihiro Tajima, Shinsuke Katoh, Hirotaka Tanaka, Takeshi Maeda, Kazunari Furusawa, Yoshihiro Kakehi, Kunika Kikumori, Masanori Kuroha
Publikováno v: Pain and Therapy, Vol 12, Iss 4, Pp 963-978 (2023)
Abstract Introduction Central neuropathic pain (CNeP) is difficult to treat and has diverse etiology, including spinal cord injury (CNePSCI), Parkinson’s disease (CNePPD), and central post-stroke pain (CPSP). The safety and efficacy of mirogabalin
Externí odkaz: https://doaj.org/article/06a24d6f6b434972b0428a128fe6fd04
Zobrazit plný text záznamu
5
Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia
Autor: Takahiro Ushida, Yoichi Katayama, Yoichi Hiasa, Makoto Nishihara, Fumihiro Tajima, Shinsuke Katoh, Hirotaka Tanaka, Takeshi Maeda, Kazunari Furusawa, Mary Richardson, Yoshihiro Kakehi, Kunika Kikumori, Masanori Kuroha
Publikováno v: Neurology.
Background and ObjectivesPatients with spinal cord injury (SCI) commonly experience central neuropathic pain (CNeP), which is challenging to treat. Mirogabalin is effective for peripheral neuropathic pain, but evidence for CNeP is lacking.MethodsThis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ab9a195b75c8fa27a77f56061f1fd9
https://pubmed.ncbi.nlm.nih.gov/36517235
Zobrazit plný text záznamu
7
Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer
Autor: Akihiko, Shimomura, Toshimi, Takano, Shunji, Takahashi, Yasuaki, Sagara, Junichiro, Watanabe, Eriko, Tokunaga, Tetsu, Shinkai, Takahiro, Kamio, Kunika, Kikumori, Emi, Kamiyama, Yoshihiko, Fujisaki, Dan, Saotome, Toshinari, Yamashita
Publikováno v: Clinical pharmacology and therapeutics.
HER2-targeted anticancer therapies may be associated with cardiovascular adverse events. This study evaluated effects of the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd, DS-8201a) on QT/QTc interval and its pharmacokinetics. P
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a042b1746966a3986c0661c306618161
https://pubmed.ncbi.nlm.nih.gov/36164935
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje